Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Don’t blame Big Pharma for insulin’s problems

Rushi Nagalla
Policy
December 4, 2022
Share
Tweet
Share

For diabetics, insulin matters as much as H2O. Unfortunately, insulin’s a hell of a lot more expensive than bottled water. High insulin prices force approximately nine million Americans to balance their wallet and well-being.

The American Action Forum reported that a type-one diabetic’s average yearly expense for insulin was $~6000 (i.e., $500/month). It’s easy to lambast Big Pharma companies for the current state of insulin’s affairs, but history and market behavior gives a bit of critical nuance. Diabetes used to be a death sentence, with only diet changes being the main tools to fight the disease over a hundred years ago. However, nutrition is a blunt instrument to blood sugar, as interest rates are to inflation and the economy. Not to mention that several patients find it difficult to adopt major lifestyle changes. In 1922, a team of doctors and biochemists produced the earliest version of lab-drawn insulin alongside Eli Lilly and the University of Toronto.

Now, that drug’s genetically modified and versatile for several diabetic issues. Today we have three major pharma companies (Eli Lilly, Novo Nordisk, and Sanofi) manufacturing various forms of what might be considered a scientific miracle. That oligopoly is part of why insulin commands a massive price. But there’s more to the insulin market than Big Pharma alone.

Insulin keeps getting expensive partly because more people are getting diagnosed with diabetes every year — which pushes up overall demand. The other factors behind rising prices stem from that market’s several players: manufacturers, wholesalers, pharmacies, pharmacy benefit managers (PBMs), health plans, and, of course, patients. Manufacturers give the drug to wholesalers, usually at a bulk discount, while paying out rebates to PBMs for higher formulary placement.

Wholesalers are the majority of insulin makers’ revenues due to pressure from PBMs. Pharmacies pay wholesalers for the product and bill health plans for reimbursement. Patients then get their insulin from the pharmacy with insurance, cash, or drug assistance programs.

Health plans cover the meds (or not) and reimburse PBMs for services. PBMs take rebates from manufacturers to, in principle, bring the overall insulin cost down. In practice, that step isn’t so clear. With the number of entities involved and the secrecy of coverage negotiations, the actual sticker price listed by insulin makers isn’t what patients pay. That being said, the list price is still a proxy for price behavior up and down most of the insulin supply chain.

Between 2014 and 2018, the average list price per 100 units of insulin rose, yet the net price (where manufacturers draw their sales from) fell. The real story is how the net cost to the insulin health care system stayed flat. Manufacturers are taking discounts, yet both health plans and pharmacy benefit managers aren’t passing those savings along to patients. Such behavior is why the middlemen’s share of insulin expenses went from 30 percent in 2014 to 53 percent by 2018. The middlemen supposedly negotiating prices down maintain their profits by keeping the savings, while drug makers want to keep their margins as well. List prices rise to compensate. The cycle continues.

Lawmakers have started to act on this phenomenon. Both states and the feds have been applying copay caps, meaning that a patient’s monthly expense for insulin would have a ceiling regardless of a health plan’s deductible. As part of the Inflation Reduction Act, Congress passed a bill limiting monthly insulin copays to $35 a month for Medicare patients. Colorado broke ground with an insulin cap in January 2020. 13 states enacted their own rules by June 2021. State-based caps mostly target patients with commercial insurance. Yet those most in need of cheaper insulin are Medicaid and uninsured patients. Neither are beneficiaries of most copay cap laws. The state-level caps do not apply to all commercial insurance plans to begin with. It’s mostly single-state health plans that have to abide by cost limits. Patients who get insurance through an employer with multi-state coverage may not qualify for insulin assistance.

While it’s a little early to gauge the price caps’ impact, such rules potentially set a precedent for less diabetes research in the future. Insulin manufacturers would likely need to accept more rebate concessions while raising list prices to compensate for potential margin declines. Eventually, the usage of insulin for the average consumer becomes untenable.

The diabetics of tomorrow, and there will be plenty, would suffer. Patients signing up for insurance now should request summaries of benefits and coverage documents as well as published insurer formularies to seek the best possible insulin coverage. Contacting a local plan broker and insurance marketplace is a more reasonable first step than waiting for lawmakers to concoct smarter insulin coverage.

Rushi Nagalla is co-founder of a dermatology practice.

Image credit: Shutterstock.com

Prev

Bulletproof backpacks: There’s more we can do [PODCAST]

December 3, 2022 Kevin 0
…
Next

7 things I’ve learned after 12 years of private relationship-based direct care in Canada

December 4, 2022 Kevin 0
…

ADVERTISEMENT

Tagged as: Diabetes, Endocrinology

Post navigation

< Previous Post
Bulletproof backpacks: There’s more we can do [PODCAST]
Next Post >
7 things I’ve learned after 12 years of private relationship-based direct care in Canada

ADVERTISEMENT

More by Rushi Nagalla

  • Is your smartwatch smart about your health?

    Rushi Nagalla
  • Make your health insurance broker a translator, not a shopper

    Rushi Nagalla
  • America trains enough doctors: Redefining medical supply and demand

    Rushi Nagalla

Related Posts

  • Why you shouldn’t be happy with $137 insulin

    Elisabeth Rosenthal, MD
  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 45-year-old woman with type 2 diabetes mellitus

    mksap
  • The people vs. opioid pharma: Pharma wins again

    Rebecca Thaxton, MD
  • Type 1 diabetes is no fun

    Ryan Ritchie
  • Questions about pharma pricing and marketing

    Martha Rosenberg
  • A medical educator’s poignant epiphany

    Robert Marion, MD

More in Policy

  • Unused IV catheters cost U.S. hospitals billions

    Piyush Pillarisetti
  • Why your health care dashboard isn’t working and how to fix it

    Dave Cummings, RN
  • Nuclear verdicts and rising costs: How inflation is reshaping medical malpractice claims

    Robert E. White, Jr. & The Doctors Company
  • How new loan caps could destroy diversity in medical education

    Caleb Andrus-Gazyeva
  • Why transplant equity requires more than access

    Zamra Amjid, DHSc, MHA
  • Ideology, not evidence, fuels the anti-trans agenda

    Andie Riffer, PhD and Shawn E. Parra, LCSW, MSW
  • Most Popular

  • Past Week

    • Why your clinic waiting room may affect patient outcomes

      Ziya Altug, PT, DPT and Shirish Sachdeva, PT, DPT | Conditions
    • The human case for preserving the nipple after mastectomy

      Thomas Amburn, MD | Conditions
    • Nuclear verdicts and rising costs: How inflation is reshaping medical malpractice claims

      Robert E. White, Jr. & The Doctors Company | Policy
    • How new loan caps could destroy diversity in medical education

      Caleb Andrus-Gazyeva | Policy
    • The ethical crossroads of medicine and legislation

      M. Bennet Broner, PhD | Conditions
    • How community and buses saved my retirement

      Raymond Abbott | Conditions
  • Past 6 Months

    • Health equity in Inland Southern California requires urgent action

      Vishruth Nagam | Policy
    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • Why primary care needs better dermatology training

      Alex Siauw | Conditions
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Why pain doctors face unfair scrutiny and harsh penalties in California

      Kayvan Haddadan, MD | Physician
  • Recent Posts

    • Coconut oil’s role in Alzheimer’s and depression

      Marc Arginteanu, MD | Conditions
    • How policy and stigma block addiction treatment

      Mariana Ndrio, MD | Physician
    • Unused IV catheters cost U.S. hospitals billions

      Piyush Pillarisetti | Policy
    • Why U.S. universities should adopt a standard pre-med major [PODCAST]

      The Podcast by KevinMD | Podcast
    • Ancient health secrets for modern life

      Larry Kaskel, MD | Conditions
    • How the internet broke the doctor-parent trust

      Wendy L. Hunter, MD | Conditions

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Why your clinic waiting room may affect patient outcomes

      Ziya Altug, PT, DPT and Shirish Sachdeva, PT, DPT | Conditions
    • The human case for preserving the nipple after mastectomy

      Thomas Amburn, MD | Conditions
    • Nuclear verdicts and rising costs: How inflation is reshaping medical malpractice claims

      Robert E. White, Jr. & The Doctors Company | Policy
    • How new loan caps could destroy diversity in medical education

      Caleb Andrus-Gazyeva | Policy
    • The ethical crossroads of medicine and legislation

      M. Bennet Broner, PhD | Conditions
    • How community and buses saved my retirement

      Raymond Abbott | Conditions
  • Past 6 Months

    • Health equity in Inland Southern California requires urgent action

      Vishruth Nagam | Policy
    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • Why primary care needs better dermatology training

      Alex Siauw | Conditions
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Why pain doctors face unfair scrutiny and harsh penalties in California

      Kayvan Haddadan, MD | Physician
  • Recent Posts

    • Coconut oil’s role in Alzheimer’s and depression

      Marc Arginteanu, MD | Conditions
    • How policy and stigma block addiction treatment

      Mariana Ndrio, MD | Physician
    • Unused IV catheters cost U.S. hospitals billions

      Piyush Pillarisetti | Policy
    • Why U.S. universities should adopt a standard pre-med major [PODCAST]

      The Podcast by KevinMD | Podcast
    • Ancient health secrets for modern life

      Larry Kaskel, MD | Conditions
    • How the internet broke the doctor-parent trust

      Wendy L. Hunter, MD | Conditions

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...